• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Regado Biosciences Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California

Posted on: Tuesday, 17 March 2009, 07:30 CDT

BASKING RIDGE, N.J., March 17 /PRNewswire/ -- Regado Biosciences, Inc. today announced that David J. Mazzo, Ph.D., President and CEO of Regado Biosciences, Inc., will present at InsideVenture's Debut Conference, March 25-26, 2009 in Santa Barbara, California. Regado Biosciences has been selected from over 170 nominations to be one of 50 top private companies showcased to long-term investors through presentations and 1-on-1 meetings at the invitation only conference. At the conference, Dr. Mazzo will provide a thorough overview of Regado Biosciences, Inc. a company which is pioneering the discovery and development of modulators-controlled aptamers for use in a variety of cardiovascular indications in acute care settings. InsideVenture's Selection Boards includes Founders and Partners of leading venture firms including NEA, Venrock, DCM, Domain, Frazier, Clarus, Oak Investment, Aisling, and Versant. Over 130 investors are represented in the selected companies.

"We are honored to support Regado Biosciences, Inc. in their private funding efforts through our online platform and at our debut transactional conference in Santa Barbara," said Mona DeFrawi, Chief Executive Officer of InsideVenture. "InsideVenture was created as a powerful and cost-effective platform to support the companies that grow our economy by facilitating their late stage and pre-IPO financing needs. Structural changes in the capital markets over the past 10 years have blocked the real path to economic growth by challenging the financing of the companies delivering valuable new products, jobs and profits for the world economy. These top 50 companies have invested in innovation, and now InsideVenture is innovating the investment process to support their continued growth."

"Regado Biosciences, Inc. is pleased to use InsideVenture's new financing platform because it provides an efficient means to access and build relationships with a number of high quality private investors," said David J. Mazzo, Ph.D., President and CEO of Regado Biosciences, Inc.

InsideVenture Investor Conference - March 25-26, Santa Barbara, California

Regado Biosciences, Inc. is one of 50 top late-stage private healthcare and technology companies seeking to raise $20-200+M or establish and develop relationships with new investors prior to an eventual IPO. The companies will present their businesses to qualified institutional buyers (QIBs), including mutual fund managers, crossover funds, late stage VC & PE funds and strategic corporate investors. Investors interested in attending the conference may apply for an InsideVenture trial membership; the conference is exclusive to members and by invitation only. The theme of this year's conference is "Investing in Innovation: Innovation in Investing." Investors should contact InsideVenture today to apply for membership and an invitation to the InsideVenture Investor Conference, March 25-26, 2009 in Santa Barbara, California.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched active control agent. This technology is being applied to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

Regado's lead program, REG1, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007), which can be used to completely or selectively lower the anticoagulant effect. Regado recently completed a phase 2a study of REG1 in percutaneous coronary intervention (PCI) and is planning the initiation of a rigorous phase 2b program in that same indication in 3Q2009.

About InsideVenture

InsideVenture is an industry sponsored financial marketing utility creating a direct private market platform for institutional and strategic investment in late-stage private companies. InsideVenture's exclusive vetting and membership requirements connect the best late-stage venture-backed companies with revered long-term institutional and strategic investors to facilitate late-stage transactions, IPO participation and aftermarket support. InsideVenture is supported by investment leaders and partners like T. Rowe Price, Wasatch Advisors, SVB Financial Group, NYSE, Alexandria Equities, Intralinks Corporation, New Enterprise Associates, Domain Associates, DCM, Venrock Associates, Versant Ventures, Frazier Healthcare Ventures, Clarus Ventures, and Aisling Capital among others. InsideVenture is based in Menlo Park, California and on the web at www.insideventure.com

SOURCE Regado Biosciences, Inc.

Source: PR Newswire

More News in this Category